{"id":"https://openalex.org/W36311596","doi":"https://doi.org/10.1021/jm010964g","title":"Novel Tricyclic-\u03b1-alkyloxyphenylpropionic Acids: Dual PPAR\u03b1/\u03b3 Agonists with Hypolipidemic and Antidiabetic Activity","display_name":"Novel Tricyclic-\u03b1-alkyloxyphenylpropionic Acids: Dual PPAR\u03b1/\u03b3 Agonists with Hypolipidemic and Antidiabetic Activity","alternate_titles":[],"publication_year":2002,"publication_date":"2002-01-23","ids":{"openalex":"https://openalex.org/W36311596","doi":"https://doi.org/10.1021/jm010964g","mag":"36311596","pmid":"https://pubmed.ncbi.nlm.nih.gov/11831892"},"language":"en","primary_location":{"id":"doi:10.1021/jm010964g","doi":"https://doi.org/10.1021/jm010964g","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm010964g","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W36311596"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022840471","display_name":"Per Sauerberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":true,"raw_author_name":"Per Sauerberg","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008784458","display_name":"Ingrid Pettersson","orcid":"https://orcid.org/0000-0001-9306-3649","observed_orcids":["https://orcid.org/0000-0001-9306-3649"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Ingrid Pettersson","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109839086","display_name":"Lone Jeppesen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Lone Jeppesen","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048297436","display_name":"Paul S. Bury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Paul S. Bury","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042764101","display_name":"John P. Mogensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"John P. Mogensen","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028655677","display_name":"Karsten Wassermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Karsten Wassermann","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013301991","display_name":"Christian Lehn Brand","orcid":"https://orcid.org/0000-0002-7355-4448","observed_orcids":["https://orcid.org/0000-0002-7355-4448"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Christian L. Brand","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041165497","display_name":"Jeppe Sturis","orcid":"https://orcid.org/0000-0001-9938-5278","observed_orcids":["https://orcid.org/0000-0001-9938-5278"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Jeppe Sturis","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015601130","display_name":"Helle F. W\u00f6ldike","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Helle F. W\u00f6ldike","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006360414","display_name":"Jan Fleckner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Jan Fleckner","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007568432","display_name":"Anne-Sofie T. Andersen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Anne-Sofie T. Andersen","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033305108","display_name":"Steen Bennike Mortensen","orcid":"https://orcid.org/0000-0002-9848-4511","observed_orcids":["https://orcid.org/0000-0002-9848-4511"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Steen B. Mortensen","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090577559","display_name":"L. Anders Svensson","orcid":"https://orcid.org/0000-0003-3357-5049","observed_orcids":["https://orcid.org/0000-0003-3357-5049"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"L. Anders Svensson","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073616733","display_name":"Hanne Borger Rasmussen","orcid":"https://orcid.org/0000-0002-2218-5646","observed_orcids":["https://orcid.org/0000-0002-2218-5646"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Hanne B. Rasmussen","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011650943","display_name":"S\u00f8ren Vig Lehmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"S\u00f8ren V. Lehmann","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023753951","display_name":"Zden\u011bk Pol\u00edvka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Zdenek Polivka","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Karel Sindelar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Karel Sindelar","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012148797","display_name":"Vladim\u00edra Panajotov\u00e1","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Vladimira Panajotova","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051883836","display_name":"Lars Ynddal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Lars Ynddal","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075548945","display_name":"Erik Max Wulff","orcid":"https://orcid.org/0000-0002-8149-3067","observed_orcids":["https://orcid.org/0000-0002-8149-3067"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210110391","display_name":"Apigenex (Czechia)","ror":"https://ror.org/01kpsvc92","country_code":"CZ","type":"company","lineage":["https://openalex.org/I4210110391"]}],"countries":["CZ","DK"],"is_corresponding":false,"raw_author_name":"Erik M. Wulff","raw_affiliation_strings":["Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk A/S, Novo Nordisk Park, 2760 M\u00e5l\u00f8v, Denmark, and RE&D VUFB, s.r.o., Podebradska 56/186, 18066 Praha 9, Czech Republic","institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5022840471"],"corresponding_institution_ids":["https://openalex.org/I189090001","https://openalex.org/I4210110391"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":4.7019,"has_fulltext":false,"cited_by_count":152,"citation_normalized_percentile":{"value":0.96442103,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"45","issue":"4","first_page":"789","last_page":"804"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pparalpha-agonists","display_name":"PPAR\u03b1 agonist","score":0.7829999923706055},{"id":"https://openalex.org/keywords/ppargamma-agonists","display_name":"PPAR\u03b3 agonists","score":1.0},{"id":"https://openalex.org/keywords/carbazole-derivatives","display_name":"carbazole derivatives","score":0.800000011920929},{"id":"https://openalex.org/keywords/hypolipidemic-activity","display_name":"hypolipidemic activity","score":0.9210000038146973},{"id":"https://openalex.org/keywords/antidiabetic-activity","display_name":"antidiabetic activity","score":0.9819999933242798},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.9350000023841858},{"id":"https://openalex.org/keywords/db-db-mice","display_name":"db/db mice","score":0.8320000171661377},{"id":"https://openalex.org/keywords/plasma-triglycerides","display_name":"plasma triglycerides","score":0.7879999876022339},{"id":"https://openalex.org/keywords/cholesterol-lowering","display_name":"cholesterol lowering","score":0.7139999866485596},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.9380000233650208},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9380000233650208},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.8759999871253967},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":1.0}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.863300085067749},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7971611022949219},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.6956660747528076},{"id":"https://openalex.org/C2781081902","wikidata":"https://www.wikidata.org/wiki/Q3539074","display_name":"Tricyclic","level":2,"score":0.6386933326721191},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6196151375770569},{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.5944939851760864},{"id":"https://openalex.org/C1292079","wikidata":"https://www.wikidata.org/wiki/Q3817769","display_name":"Transactivation","level":4,"score":0.5521954298019409},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5389178395271301},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.48190075159072876},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4739812910556793},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34244096279144287},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.34238386154174805},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.2850525379180908},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.24282583594322205},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.21537700295448303},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.17500552535057068},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.1675196886062622},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0772925615310669},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.05762207508087158},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077154","descriptor_name":"Rosiglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077205","descriptor_name":"Pioglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002227","descriptor_name":"Carbazoles","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D002227","descriptor_name":"Carbazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002227","descriptor_name":"Carbazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002227","descriptor_name":"Carbazoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D002784","descriptor_name":"Cholesterol","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002791","descriptor_name":"Cholesterol, Dietary","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005951","descriptor_name":"Glucose Tolerance Test","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008958","descriptor_name":"Models, Molecular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009687","descriptor_name":"Nuclear Proteins","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D010666","descriptor_name":"Phenylpropionates","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D010666","descriptor_name":"Phenylpropionates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010666","descriptor_name":"Phenylpropionates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010666","descriptor_name":"Phenylpropionates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013237","descriptor_name":"Stereoisomerism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D014157","descriptor_name":"Transcription Factors","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018160","descriptor_name":"Receptors, Cytoplasmic and Nuclear","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D018360","descriptor_name":"Crystallography, X-Ray","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm010964g","doi":"https://doi.org/10.1021/jm010964g","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm010964g","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:11831892","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11831892","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W255489331","https://openalex.org/W1527827101","https://openalex.org/W1969478165","https://openalex.org/W1972766406","https://openalex.org/W1977666051","https://openalex.org/W1980743114","https://openalex.org/W1981213532","https://openalex.org/W1987652896","https://openalex.org/W2000840258","https://openalex.org/W2002438078","https://openalex.org/W2015279471","https://openalex.org/W2021435938","https://openalex.org/W2027324370","https://openalex.org/W2041229954","https://openalex.org/W2047730466","https://openalex.org/W2050671706","https://openalex.org/W2051824140","https://openalex.org/W2053174288","https://openalex.org/W2054851194","https://openalex.org/W2060087476","https://openalex.org/W2060752803","https://openalex.org/W2065876677","https://openalex.org/W2068105284","https://openalex.org/W2080653934","https://openalex.org/W2084891561","https://openalex.org/W2092923062","https://openalex.org/W2102005461","https://openalex.org/W2110165121","https://openalex.org/W2113456624","https://openalex.org/W2118079014","https://openalex.org/W2131124255","https://openalex.org/W2152039811","https://openalex.org/W2166760114","https://openalex.org/W2171716790","https://openalex.org/W2317247840","https://openalex.org/W2323568886","https://openalex.org/W2328529137","https://openalex.org/W2950926184"],"related_works":["https://openalex.org/W2079500225","https://openalex.org/W2081616756","https://openalex.org/W2016083223","https://openalex.org/W2008062584","https://openalex.org/W7156668969","https://openalex.org/W1968473847","https://openalex.org/W1971784896","https://openalex.org/W2012818636","https://openalex.org/W2158507833","https://openalex.org/W2050691910"],"abstract_inverted_index":{"Synthesis":[0],"and":[1,14,18,38,70,83],"structure-activity":[2],"relationships":[3],"of":[4,25,50,100,103,116],"tricyclic":[5],"alpha-ethoxy-phenylpropionic":[6],"acid":[7],"derivatives":[8],"guided":[9],"by":[10,61],"in":[11,45,74,85,95,113,117],"vitro":[12,118],"PPARalpha":[13,33,97],"PPARgamma":[15,39,76],"transactivation":[16],"data":[17],"computer":[19],"modeling":[20],"led":[21],"to":[22],"the":[23,26,56,101,112],"identification":[24],"novel":[27],"carbazole":[28],"analogue,":[29],"3q,":[30],"with":[31,53,67],"dual":[32],"(EC(50)":[34,40],"=":[35,41],"0.36":[36],"microM)":[37,43],"0.17":[42],"activity":[44,115],"vitro.":[46],"Ten":[47],"days":[48,92],"treatment":[49],"db/db":[51],"mice":[52],"3q":[54,79],"improved":[55,111],"insulin":[57],"sensitivity,":[58],"as":[59],"measured":[60],"OGTT,":[62],"better":[63],"than":[64],"that":[65,107],"seen":[66],"both":[68],"pioglitazone":[69],"rosiglitazone":[71],"treatment,":[72,93],"suggesting":[73],"vivo":[75,96,114],"activity.":[77,98],"Likewise,":[78],"lowered":[80],"plasma":[81],"triglycerides":[82],"cholesterol":[84,87],"high":[86],"fed":[88],"rats":[89],"after":[90],"4":[91],"indicating":[94],"Investigations":[99],"pharmacokinetics":[102],"selected":[104],"compounds":[105],"suggested":[106],"extended":[108],"drug":[109],"exposure":[110],"active":[119],"compounds.":[120]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W36311596","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
